Bluefin Biomedicine has a total of 44 patents globally, out of which 9 have been granted. Of these 44 patents, more than 81% patents are active. The United States of America is where Bluefin Biomedicine has filed the maximum number of patents, followed by Canada and Japan. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Bluefin Biomedicine.
Bluefin Biomedicine was founded in 2016. Bluefin Biomedicine is a privately held firm that focuses on the discovery of novel cancer antigens and the development of next-generation cancer treatments. The complex tumor specimens are analysed using patented, state-of-the-art protein detection techniques to identify cancer antigens that are expressed differently and can be targeted by antibody treatments.
Do read about some of the most popular patents of Bluefin Biomedicine which have been covered by us in this article and also you can find Bluefin Biomedicine patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Bluefin Biomedicine patent portfolio.
How many patents does Bluefin Biomedicine have?
Bluefin Biomedicine has a total of 44 patents globally. These patents belong to 10 unique patent families. Out of 44 patents, 36 patents are active.
How Many Patents did Bluefin Biomedicine File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Bluefin Biomedicine Applications Filed | Bluefin Biomedicine Patents Granted |
| 2023 | 2 | 4 |
| 2022 | 5 | 4 |
| 2021 | 1 | – |
| 2020 | 2 | – |
| 2019 | 1 | 1 |
| 2018 | 20 | – |
| 2017 | 12 | – |
| 2014 | 2 | – |
How many Bluefin Biomedicine patents are Alive/Dead?
Worldwide Patents
How Many Patents did Bluefin Biomedicine File in Different Countries?
Countries in which Bluefin Biomedicine Filed Patents
| Country | Patent |
| United States of America | 13 |
| Canada | 7 |
| Japan | 6 |
| Europe | 6 |
| China | 3 |
| Hong Kong (S.A.R.) | 2 |
Where are Research Centers of Bluefin Biomedicine Patents Located?
The Research Center for Bluefin Biomedicine is the United States of America.
What Percentage of Bluefin Biomedicine US Patent Applications Were Granted?
Bluefin Biomedicine (Excluding its subsidiaries) has filed 10 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 5 have been granted leading to a grant rate of 100%.
Below are the key stats of Bluefin Biomedicine patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Bluefin Biomedicine?
| Law Firm | Total Applications | Success Rate |
| Mccarter & English Llp Boston | 6 | 100.00% |
| Morgan Lewis & Bockius Llp Ph | 2 | 0% |
| Klarquist Sparkman Llp | 1 | 100.00% |
| Procopio Cory Hargreaves & Savitch Llp | 1 | 100.00% |
List of Bluefin Biomedicine patents
| Bluefin Biomedicine Patents | Title |
| US11702481B2 | Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof |
| US11634486B2 | Anti-Sez6L2 Antibodies And Antibody Drug Conjugates |
| US11434303B2 | Anti-Ly6H Antibodies And Antibody Drug Conjugates |
| US11312769B2 | Anti-Tmeff1 Antibodies And Antibody Drug Conjugates |
| US11267886B2 | Anti-Ilt3 Antibodies And Antibody Drug Conjugates |
| US11248054B2 | Anti-Il1Rap Antibodies And Antibody Drug Conjugates |
| US10208125B2 | Anti-Mucin 1 Binding Agents And Uses Thereof |
| US20230331839A1 | Anti-Sez6L2 Antibodies And Antibody Drug Conjugates |
| US20230192885A1 | Anti-Ly6H Antibodies And Antibody Drug Conjugates |
| US20230069760A1 | Anti-Vtcn1 Antibodies And Antibody Drug Conjugates |
| US20220298239A1 | Anti-Tmeff1 Antibodies And Antibody Drug Conjugates |
| US20220267455A1 | Anti-Il1Rap Antibodies And Antibody Drug Conjugates |
| US20220227863A1 | Anti-Ilt3 Antibodies And Antibody Drug Conjugates |
| EP3580239A4 | Anti-Ilt3 Antibodies And Antibody Drug Conjugates |
| EP3638697A4 | Anti-Il1Rap Antibodies And Antibody Drug Conjugates |
| EP3601360A4 | Anti-Tmeff1 Antibodies And Antibody Drug Conjugates |
| EP3612567A4 | Anti-Vtcn1 Antibodies And Antibody Drug Conjugates |
| EP3559043A4 | Anti-Sez6L2 Antibodies And Antibody Drug Conjugates |
| EP3554544A4 | Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof |
| CN110997725A | Anti-Il1Rap Antibodies And Antibody Drug Conjugates |
| CN110234348A | Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof |
| CN110121507A | Anti-Sez6L2 Antibodies And Antibody Drug Conjugates |
| CA3066918A1 | Anti-Il1Rap Antibodies And Antibody Drug Conjugates |
| CA3064697A1 | Anti-Vtcn1 Antibodies And Antibody Drug Conjugates |
| CA3055305A1 | Anti-Tmeff1 Antibodies And Antibody Drug Conjugates |
| CA3053164A1 | Anti-Ilt3 Antibodies And Antibody Drug Conjugates |
| CA3048224A1 | Anti-Sez6L2 Antibodies And Antibody Drug Conjugates |
| CA3047115A1 | Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof |
| CA2954859A1 | Anti-Mucin 1 Binding Agents And Uses Thereof |
| JP7350313B2 | Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof |
| JP7264482B2 | Anti-Sez6L2 Antibodies And Antibody Drug Conjugates |
| JP2023022328A5 | Anti-Sez6L2 Antibodies And Antibody Drug Conjugates |
| JP2023093685A | Anti-Il1Rap Antibodies And Antibody Drug Conjugates |
| JP2022101693A5 | Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof |
| HK40027179A | Anti-Il1Rap Antibodies And Antibody Drug Conjugates |
| HK40014209A | Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof |
| WO2018175740A8 | Anti-Tmeff1 Antibodies And Antibody Drug Conjugates |
| WO2018231827A9 | Anti-Il1Rap Antibodies And Antibody Drug Conjugates |
| WO2018119351A8 | Anti-Sez6L2 Antibodies And Antibody Drug Conjugates |
| WO2019006162A1 | Anti-Ly6H Antibodies And Antibody Drug Conjugates |
| WO2018195302A1 | Anti-Vtcn1 Antibodies And Antibody Drug Conjugates |
| WO2018148494A1 | Anti-Ilt3 Antibodies And Antibody Drug Conjugates |
| WO2018112334A1 | Anti-Cub Domain-Containing Protein 1 (Cdcp1) Antibodies, Antibody Drug Conjugates, And Methods Of Use Thereof |
| JP2020527332A5 | Anti-Il1Rap Antibodies And Antibody Drug Conjugates |
What are Bluefin Biomedicine key innovation segments?
What Technologies are Covered by Bluefin Biomedicine?
The chart below distributes patents filed by Bluefin Biomedicine